Parkman Healthcare Partners
Parkman Healthcare Partners is a healthcare-focused investment firm established in 2018 and located in Stamford, Connecticut. The firm specializes in employing long/short, sector-oriented, and fundamental equity investment strategies. It targets small and mid-cap companies within various segments of the healthcare industry, including medical devices, diagnostics, pharmaceuticals, biotechnology, life sciences, and general health care. By concentrating on these sectors, Parkman Healthcare Partners aims to identify and capitalize on investment opportunities that drive growth and innovation in the healthcare landscape.
VYNE Therapeutics
Post in 2023
VYNE Therapeutics Inc. is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for dermatological conditions. It offers AMZEEQ, a topical minocycline treatment for non-nodular moderate-to-severe acne vulgaris in patients aged 9 and older. The company is advancing its pipeline with FMX103, currently in Phase III clinical trials for moderate-to-severe papulopustular rosacea in adults, and FCD105, a topical combination foam under investigation in Phase II trials for moderate-to-severe acne vulgaris. Additionally, VYNE is developing Serlopitant, an oral NK1 receptor antagonist aimed at addressing pruritus associated with prurigo nodularis, as well as exploring therapies for other immuno-inflammatory conditions. Formerly known as Menlo Therapeutics Inc., the company rebranded in September 2020 and is headquartered in Bridgewater, New Jersey.
Immunic Therapeutics
Post in 2022
Immunic Therapeutics is a clinical-stage biopharmaceutical company focused on developing selective oral immunology therapies to treat chronic inflammatory and autoimmune diseases. The company's pipeline includes three small molecule products. The lead program, IMU-838, is a selective immune modulator that blocks the enzyme DHODH, inhibiting the metabolism of activated immune cells and exhibiting antiviral effects. It is being developed for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, targets psoriasis, castration-resistant prostate cancer, and Guillain-Barré syndrome. Additionally, IMU-856 aims to restore intestinal barrier function for diseases involving bowel barrier dysfunction.
Stereotaxis, Inc. specializes in the design, manufacture, and marketing of robotic magnetic navigation systems aimed at enhancing the treatment of arrhythmias and coronary artery disease. Its core products include the Genesis and Niobe systems, which facilitate complex interventional procedures by enabling image-guided catheter and guidewire navigation within the heart. The company also offers the Vdrive system, which provides stability for diagnostic and therapeutic devices, and the Odyssey solution, a real-time information management system for interventional labs. Additionally, Stereotaxis produces various disposable components, such as automated catheter advancement devices, and collaborates with Osypka AG to develop next-generation magnetic ablation catheters. Founded in 1990 and headquartered in St. Louis, Missouri, Stereotaxis holds over 100 patents and markets its products through a combination of direct sales and partnerships with distributors and sales agents. The company's innovations aim to improve patient care through enhanced precision, safety, and efficiency in interventional procedures.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.